Sarepta Therapeutics CSO Gilmore MMSc's 2019 pay slips 20% to $5.2M
Sarepta Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 21, 2020
Sarepta Therapeutics reported fiscal year 2019 executive compensation information on April 21, 2020.
In 2019, five executives at Sarepta Therapeutics received on average a compensation package of $4.1M, a 10% increase compared to previous year.
Average pay of disclosed executives at Sarepta Therapeutics
Gilmore O'Neill, M.B., M.M.Sc, Chief Scientific Officer, received $5.2M in total, which decreased by 20% compared to 2018. 82% of MMSc's compensation, or $4.2M, was in option awards. MMSc also received $354K in non-equity incentive plan, $564K in salary, as well as $15K in other compensation.
For fiscal year 2019, the median employee pay was $290,714 at Sarepta Therapeutics. Therefore, the ratio of Gilmore O'Neill, M.B., M.M.Sc's pay to the median employee pay was 18 to one.
Sandesh Mahatme, Chief Financial Officer, received a compensation package of $5.2M, which increased by 22% compared to previous year. 82% of the compensation package, or $4.2M, was in option awards.
William Ciambrone, Executive Vice President, Technical Operations, earned $4.3M in 2019.
David Tyronne Howton, Jr, General Counsel, received $4.2M in 2019, which increases by 34% compared to 2018.
Douglas Ingram, Chief Executive Officer, earned $1.4M in 2019, a 3% decrease compared to previous year.
Related executives
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
Sandesh Mahatme
Sarepta Therapeutics
Chief Financial Officer
David Howton
Sarepta Therapeutics
General Counsel
Gilmore MMSc
Sarepta Therapeutics
Chief Scientific Officer
William Ciambrone
Sarepta Therapeutics
Executive Vice President, Technical Operations
You may also like
Source: SEC filing on April 21, 2020.